Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation

Orally available antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are necessary because of the continuous circulation of new variants that challenge immunized individuals. Because severe COVID-19 is a virus-triggered immune and inflammatory dysfunction, molecules endow...

Descripción completa

Detalles Bibliográficos
Autores principales: Souza, Thiago Moreno L., Pinho, Vagner D., Setim, Cristina F., Sacramento, Carolina Q., Marcon, Rodrigo, Fintelman-Rodrigues, Natalia, Chaves, Otavio A., Heller, Melina, Temerozo, Jairo R., Ferreira, André C., Mattos, Mayara, Momo, Patrícia B., Dias, Suelen S. G., Gesto, João S. M., Pereira-Dutra, Filipe, Viola, João P. B., Queiroz-Junior, Celso Martins, Guimarães, Lays Cordeiro, Chaves, Ian Meira, Guimarães, Pedro Pires Goulart, Costa, Vivian Vasconcelos, Teixeira, Mauro Martins, Bou-Habib, Dumith Chequer, Bozza, Patrícia T., Aguillón, Anderson R., Siqueira-Junior, Jarbas, Macedo-Junior, Sergio, Andrade, Edineia L., Fadanni, Guilherme P., Tolouei, Sara E. L., Potrich, Francine B., Santos, Adara A., Marques, Naiani F., Calixto, João B., Rabi, Jaime A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837764/
https://www.ncbi.nlm.nih.gov/pubmed/36639383
http://dx.doi.org/10.1038/s41467-023-35928-z

Ejemplares similares

Ejemplares similares